CARLOMAGNO, FRANCESCA
CARLOMAGNO, FRANCESCA
Dipartimento di Medicina molecolare e Biotecnologie mediche
NCOA4 inhibits initiation of DNA replication to maintain genome stability
2012 Bellelli, Roberto; Castellone, MARIA DOMENICA; Guida, Teresa; Annamaria, Cirafici; Francesco, Merolla; Livia, Provitera; Roberto, Limongello; Nina, Dathan; Grieco, Domenico; Costanzo, Vincenzo; Fusco, Alfredo; Santoro, Massimo; Carlomagno, Francesca
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati
2009 Santoro, Massimo; Carlomagno, F; Vecchio, Giancarlo
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
2007 Guida, Teresa; Anaganti, S; Provitera, L; Gedrich, R; Sullivan, E; Wilhelm, Sm; Santoro, Massimo; Carlomagno, Francesca
Molecular targeting of the RET kinase in thyroid cancer
2007 Santoro, Massimo; Carlomagno, F.
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer
2012 Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi.
2007 Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32
1994 Wong, Wt; Kraus, Mh; Carlomagno, Francesca; Zelano, A; Druck, T; Croce, Cm; Heubener, K; DI FIORE, Pp
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase
2003 Melillo, ROSA MARINA; Carlomagno, Francesca; Oriente, F; Miele, C; Fiory, Francesca; Santopietro, S; Castellone, Md; Beguinot, F; Santoro, Massimo; Formisano, Pietro
Different mutations of the RET gene cause different human tumoral diseases.
1999 Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; R., Visconti; DE VITA, Gabriella; G., Salvatore; Fusco, Alfredo; Vecchio, Giancarlo
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret
1998 Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, ROSA MARINA; Bucci, C; DE FRANCISCIS, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M.
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A
1994 Quadro, L; Panariello, L; Salvatore, D; Carlomagno, Francesca; DEL PRETE, M; Nunziata, V; Colantuoni, V; DI GIOVANNI, G; Brandi, Ml; Mannelli, M; Gheri, R; Verga, U; Libroia, A; Berger, N; Fusco, Alfredo; Grieco, M; Santoro, M.
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
2009 Nappi, T.; Salerno, P.; Zitzelsberger, H.; Carlomagno, Francesca; Salvatore, G.; Santoro, Massimo
RET\PTC activation in human thyroid carcinomas
1995 Fusco, Alfredo; Santoro, Massimo; Grieco, M.; Carlomagno, Francesca; Dathan, N.; Fabien, N.; Berlingieri, M. T.; Li, Z.; de franciscis, V.; Salvatore, Domenico; Melillo, ROSA MARINA; Portella, Giuseppe; Cerrato, A.; Colantuoni, V.; Vecchio, Giancarlo
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes
2002 Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas
2003 Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.
2006 Santoro, Massimo; Carlomagno, Francesca
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B
1995 Santoro, Massimo; Carlomagno, Francesca; A., Romano; D. D., Bottaro; N. A., Dathan; M., Grieco; Fusco, Alfredo; Vecchio, Giancarlo; B., Matoskova; M. H., Kraus; P. P., Di Fiore
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage.
2007 Allocca, M; DI VICINO, U; Petrillo, M; Carlomagno, Francesca; Domenici, L; Auricchio, Alberto
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
1998 G., Tallini; Santoro, Massimo; M., Helie; Carlomagno, Francesca; G., Salvatore; G., Chiappetta; M. L., Carcangiu; Fusco, Alfredo
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2)
2003 Carlomagno, Francesca; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo
Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
---|---|---|---|---|
NCOA4 inhibits initiation of DNA replication to maintain genome stability | 4.2 Abstract in Atti di convegno | 2012 | Bellelli, Roberto; Castellone, MARIA DOMENICA; Guida, Teresa; Annamaria, Cirafici; Francesco, Merolla; Livia, Provitera; Roberto, Limongello; Nina, Dathan; Grieco, Domenico; Costanzo, Vincenzo; Fusco, Alfredo; Santoro, Massimo; Carlomagno, Francesca | |
I geni oncosoppressori in "Patologia Generale" IV Ed, Pontieri-Russo-Frati | 3.1 Monografia o trattato scientifico | 2009 | Santoro, Massimo; Carlomagno, F; Vecchio, Giancarlo | |
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. | 1.1 Articolo in rivista | 2007 | Guida, Teresa; Anaganti, S; Provitera, L; Gedrich, R; Sullivan, E; Wilhelm, Sm; Santoro, Massimo; Carlomagno, Francesca | |
Molecular targeting of the RET kinase in thyroid cancer | 8.02 Comunicazioni a Convegni o Seminari | 2007 | Santoro, Massimo; Carlomagno, F. | |
Therapeutic strategies to target the receptor tyrosine kinase AXL in thyroid cancer | 4.2 Abstract in Atti di convegno | 2012 | Gnanaprakasam, Krisnamoorthy; Guida, Teresa; Visciano, Carla; Liotti, Federica; Carlomagno, Francesca; Melillo, ROSA MARINA | |
Basi molecolari delle nuove terapie: inibitori delle protein-chinasi. | 2.1 Contributo in volume (Capitolo o Saggio) | 2007 | Santoro, Massimo; Salvatore, G.; Carlomagno, F.; Fusco, Alfredo | |
The Human Eps15 gene encoding a tyrosine kinase substrate is conserved in evolution and map to 1p31-1p32 | 1.1 Articolo in rivista | 1994 | Wong, Wt; Kraus, Mh; Carlomagno, Francesca; Zelano, A; Druck, T; Croce, Cm; Heubener, K; DI FIORE, Pp | |
Protein kinase Calpha activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase | 1.1 Articolo in rivista | 2003 | Melillo, ROSA MARINA; Carlomagno, Francesca; Oriente, F; Miele, C; Fiory, Francesca; Santopietro, S; Castellone, Md; Beguinot, F; Santoro, Massimo; Formisano, Pietro | |
Different mutations of the RET gene cause different human tumoral diseases. | 1.1 Articolo in rivista | 1999 | Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; R., Visconti; DE VITA, Gabriella; G., Salvatore; Fusco, Alfredo; Vecchio, Giancarlo | |
Signalling of the Ret receptor tyrosine kinase through the c-Jun N-terminal Protein Kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret | 1.1 Articolo in rivista | 1998 | Chiariello, M; Visconti, R; Carlomagno, Francesca; Melillo, ROSA MARINA; Bucci, C; DE FRANCISCIS, V; Fox, Gm; Jing, S; Coso, Om; Gutkind, Sj; Fusco, Alfredo; Santoro, M. | |
Frequent RET proto-oncogene mutations in multiple endocrine neoplasia type 2A | 1.1 Articolo in rivista | 1994 | Quadro, L; Panariello, L; Salvatore, D; Carlomagno, Francesca; DEL PRETE, M; Nunziata, V; Colantuoni, V; DI GIOVANNI, G; Brandi, Ml; Mannelli, M; Gheri, R; Verga, U; Libroia, A; Berger, N; Fusco, Alfredo; Grieco, M; Santoro, M. | |
Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. | 1.1 Articolo in rivista | 2009 | Nappi, T.; Salerno, P.; Zitzelsberger, H.; Carlomagno, Francesca; Salvatore, G.; Santoro, Massimo | |
RET\PTC activation in human thyroid carcinomas | 1.1 Articolo in rivista | 1995 | Fusco, Alfredo; Santoro, Massimo; Grieco, M.; Carlomagno, Francesca; Dathan, N.; Fabien, N.; Berlingieri, M. T.; Li, Z.; de franciscis, V.; Salvatore, Domenico; Melillo, ROSA MARINA; Portella, Giuseppe; Cerrato, A.; Colantuoni, V.; Vecchio, Giancarlo | |
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes | 1.1 Articolo in rivista | 2002 | Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Napolitano, M.; Vecchio, Giancarlo; Fusco, Alfredo; Gazit, A.; Levitzki, A.; Santoro, Massimo | |
Genetic Alterations in differentiated thyroid cancer:what can be expected for gene expression profiling of thyroid carcinomas | 1.1 Articolo in rivista | 2003 | Santoro, Massimo; Melillo, ROSA MARINA; Carlomagno, Francesca; Castellone, MARIA DOMENICA; Vitagliano, Donata; Guida, Teresa; Vecchio, Giancarlo; Fusco, Alfredo | |
Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. | 1.1 Articolo in rivista | 2006 | Santoro, Massimo; Carlomagno, Francesca | |
Activation of RET as a dominant transforming gene by germline mutatios of MEN2A and MEN2B | 1.1 Articolo in rivista | 1995 | Santoro, Massimo; Carlomagno, Francesca; A., Romano; D. D., Bottaro; N. A., Dathan; M., Grieco; Fusco, Alfredo; Vecchio, Giancarlo; B., Matoskova; M. H., Kraus; P. P., Di Fiore | |
Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage. | 1.1 Articolo in rivista | 2007 | Allocca, M; DI VICINO, U; Petrillo, M; Carlomagno, Francesca; Domenici, L; Auricchio, Alberto | |
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. | 1.1 Articolo in rivista | 1998 | G., Tallini; Santoro, Massimo; M., Helie; Carlomagno, Francesca; G., Salvatore; G., Chiappetta; M. L., Carcangiu; Fusco, Alfredo | |
Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) | 1.1 Articolo in rivista | 2003 | Carlomagno, Francesca; Vitagliano, D; Guida, T; Basolo, F; Castellone, Md; Melillo, ROSA MARINA; Fusco, Alfredo; Santoro, Massimo |